SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

ANAB

AnaptysBio, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor the upcoming spin-off execution and Phase 1b data readouts for ANB033 in 2026–2027. The strong Jemperli commercial trajectory supports near-term royalty growth, while the separation creates optionality between a pure-play royalty vehicle and a clinical-stage biotech.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$40.37
T+0 close · Mar 3, 2026 · via day close
Latest settled
+41.26%
T+60 · $57.02
Vs SPY
+31.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $40.37entry
  2. T+1 · 9mo ago −5.40%α −4.83% · $38.19
  3. T+5 · 8mo ago +6.80%α +8.14% · $43.11
  4. T+20 · 8mo ago −6.31%α −1.89% · $37.82
  5. T+60 · 6mo ago +41.26%α +31.17% · $57.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli royalties and milestones from GSK, including a $75M milestone payment. Collaboration revenue more than doubled, and the company confirmed progress toward a Q2 2026 spin-off of its biopharma assets into First Tracks Biotherapeutics. Despite a net loss for the year, cash remains robust at $311.6M, and the royalty outlook is bullish with >$390M in annualized royalties expected by 2029.

Key Financial Metrics

Revenue
$234.6M
+156.5% YoY
EPS
$-0.46

Key Facts

  • Collaboration revenue was $108.2M (Q4) and $234.6M (full year 2025), up from $43.1M and $91.3M in 2024.
  • Jemperli achieved $1B in global sales in Nov 2025, triggering a $75M milestone payment to Anaptys.
  • Jemperli royalties grew 103% YoY to $96.0M for the year, with a $1.4B annualized run rate in Q4.
  • Anaptys expects >$390M in annualized Jemperli royalties by 2029 at GSK's peak sales guidance of >$2.7B.
  • Cash and investments totaled $311.6M as of Dec 31, 2025, down from $420.8M due to operating use and share repurchases.
  • Company repurchased 11.2% of shares outstanding ($68.6M) under its $175M buyback program.
  • Spin-off of biopharma operations into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially as early as late April.
  • Phase 1b trials for ANB033 in celiac disease and eosinophilic esophagitis ongoing, with data expected in Q4 2026 and 2027, respectively.

Financial Impact

Revenue more than doubled YoY to $234.6M; Jemperli royalties now on a $1.4B annualized run rate, implying significant future royalty growth. Expected peak annual royalties >$390M.

revenueroyaltiescasheps

Risk Factors

  • Spin-off timing or structure could change, creating uncertainty.
  • Clinical development risks for ANB033, rosnilimab, and ANB101 remain high.
  • Future royalty payments depend on GSK achieving peak sales guidance, which is not guaranteed.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248938

Track record

28 reports on ANAB

Performance horizon

10 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +24.79% at T+60 after the Jun 29, 2026 report. 12 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
  2. Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
  4. Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
  6. Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
  7. Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
  10. Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026